ARDIZZONI, ANDREA
 Distribuzione geografica
Continente #
EU - Europa 135
AS - Asia 56
NA - Nord America 39
SA - Sud America 3
Totale 233
Nazione #
IT - Italia 130
US - Stati Uniti d'America 37
CN - Cina 17
BD - Bangladesh 15
SG - Singapore 11
VN - Vietnam 11
CA - Canada 2
FR - Francia 2
AR - Argentina 1
BR - Brasile 1
DE - Germania 1
EC - Ecuador 1
FI - Finlandia 1
HU - Ungheria 1
JP - Giappone 1
KW - Kuwait 1
Totale 233
Città #
Genoa 88
Vado Ligure 21
San Jose 11
Rapallo 10
Buffalo 4
Genova 4
New York 4
Ho Chi Minh City 3
Singapore 3
Ashburn 2
Beijing 2
Lauterbourg 2
Alassio 1
Artena 1
Bari 1
Boardman 1
Budapest 1
Bunn 1
Bắc Giang 1
Can Tho 1
Cleveland Heights 1
Florence 1
Frankfurt am Main 1
Haiphong 1
Hanoi 1
Helsinki 1
Hải Dương 1
Kuwait City 1
Los Angeles 1
Marieville 1
Naples 1
Newark 1
Nha Trang 1
Norfolk 1
Orlando 1
Quincy 1
Quito 1
Quận Ninh Kiều 1
Rende 1
Rome 1
Saint Johns 1
Salvador 1
San Juan Bautista 1
St Louis 1
Tokyo 1
Toronto 1
Utica 1
Totale 189
Nome #
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 93
Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma 52
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer 52
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study 42
Totale 239
Categoria #
all - tutte 1.080
article - articoli 1.080
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.160


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227 0 0 0 0 0 0 0 0 4 0 1 2
2022/202316 4 0 0 1 2 0 0 6 2 0 1 0
2023/202417 0 3 1 6 0 1 0 0 0 0 3 3
2024/202559 5 4 2 4 5 5 2 12 4 3 7 6
2025/2026140 11 3 8 11 17 6 16 6 8 4 25 25
Totale 239